Globe Newswire (Thu, 8-Jan 8:00 AM ET)
Market Chameleon (Tue, 23-Dec 5:30 AM ET)
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Bone Biologics trades on the NASDAQ stock market under the symbol BBLG.
As of March 24, 2026, BBLG stock price declined to $1.14 with 11,821 million shares trading.
BBLG has a beta of 0.56, meaning it tends to be less sensitive to market movements. BBLG has a correlation of 0.01 to the broad based SPY ETF.
BBLG has a market cap of $2.05 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BBLG traded as high as $4,166.83 and as low as $1.11.
BBLG has underperformed the market in the last year with a price return of -78.4% while the SPY ETF gained +17.1%. BBLG has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.5% and -6.6%, respectively, while the SPY returned -4.8% and -3.4%, respectively.
BBLG support price is $1.11 and resistance is $1.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBLG shares will trade within this expected range on the day.
